IN2012DN03182A - - Google Patents

Download PDF

Info

Publication number
IN2012DN03182A
IN2012DN03182A IN3182DEN2012A IN2012DN03182A IN 2012DN03182 A IN2012DN03182 A IN 2012DN03182A IN 3182DEN2012 A IN3182DEN2012 A IN 3182DEN2012A IN 2012DN03182 A IN2012DN03182 A IN 2012DN03182A
Authority
IN
India
Prior art keywords
compounds
disclosed
methods
intermediates
synthesis
Prior art date
Application number
Inventor
Chakrapani Subramanyam
Travis T Wager
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of IN2012DN03182A publication Critical patent/IN2012DN03182A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Abstract

Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula (I), as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
IN3182DEN2012 2009-10-28 2010-10-20 IN2012DN03182A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25550609P 2009-10-28 2009-10-28
PCT/IB2010/054749 WO2011051858A1 (en) 2009-10-28 2010-10-20 Imidazole derivatives as casein kinase inhibitors

Publications (1)

Publication Number Publication Date
IN2012DN03182A true IN2012DN03182A (en) 2015-09-25

Family

ID=43301770

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3182DEN2012 IN2012DN03182A (en) 2009-10-28 2010-10-20

Country Status (23)

Country Link
US (1) US8518944B2 (en)
EP (1) EP2493876B1 (en)
JP (1) JP5784620B2 (en)
KR (1) KR101421852B1 (en)
CN (1) CN102686580B (en)
AR (1) AR078797A1 (en)
AU (1) AU2010311035B2 (en)
CA (1) CA2777632C (en)
DK (1) DK2493876T3 (en)
ES (1) ES2460065T3 (en)
HK (1) HK1171220A1 (en)
HR (1) HRP20140252T1 (en)
IL (1) IL219190A0 (en)
IN (1) IN2012DN03182A (en)
MX (1) MX2012004997A (en)
PL (1) PL2493876T3 (en)
PT (1) PT2493876E (en)
RS (1) RS53246B (en)
SI (1) SI2493876T1 (en)
TW (1) TW201125864A (en)
UY (1) UY32977A (en)
WO (1) WO2011051858A1 (en)
ZA (1) ZA201202776B (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007334260A1 (en) 2006-11-15 2008-06-26 Massachusetts Eye & Ear Infirmary Generation of inner ear cells
PL3181133T3 (en) * 2010-12-20 2019-12-31 Pfizer Inc. Novel fused pyridine compounds as casein kinase inhibitors
US9556179B2 (en) 2012-12-21 2017-01-31 Bristol-Myers Squibb Company Substituted imidazoles as casein kinase 1 D/E inhibitors
US9732065B2 (en) 2013-05-30 2017-08-15 Sumitomo Dainippon Pharma Co., Ltd. Cyclic aminomethyl pyrimidine derivative
ES2926931T3 (en) 2014-02-07 2022-10-31 Agency Science Tech & Res Casein kinase 1 inhibitors based on 2,4,5-tri-substituted azoles as inducers of cardiomyogenesis
WO2016022776A2 (en) 2014-08-06 2016-02-11 Massachusetts Eye And Ear Infirmary Increasing atoh1 life to drive sensorineural hair cell differentiantion
CN113350353A (en) 2015-03-23 2021-09-07 墨尔本大学 Treatment of respiratory diseases
WO2017096233A1 (en) * 2015-12-04 2017-06-08 Massachusetts Eye And Ear Infirmary Treatment of hearing loss by inhibition of casein kinase 1
WO2017132530A1 (en) 2016-01-29 2017-08-03 Massachusetts Eye And Ear Infirmary Expansion and differentiation of inner ear supporting cells and methods of use thereof
AU2018262108A1 (en) * 2017-05-03 2019-11-21 The University Of Melbourne Compounds for the treatment of respiratory diseases
US10973820B2 (en) 2017-12-13 2021-04-13 Facio Intellectual Property B.V. Compounds for treatment of diseases related to DUX4 expression
EP3846818A1 (en) * 2018-09-09 2021-07-14 Qanatpharma AG Use of casein kinase 1 inhibitors for treating vascular diseases
CN113272298A (en) * 2018-11-07 2021-08-17 墨尔本大学 Compounds and compositions for the treatment of respiratory diseases
TW202112368A (en) 2019-06-13 2021-04-01 荷蘭商法西歐知識產權股份有限公司 Inhibitor combinations for treatment of diseases related to dux4 expression
WO2021190616A1 (en) * 2020-03-27 2021-09-30 Gritscience Biopharmaceuticals Co., Ltd. Methods for inhibiting casein kinases
EP4126878A1 (en) * 2020-03-27 2023-02-08 Gritscience Biopharmaceuticals Co., Ltd. Compounds as casein kinase inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06502178A (en) * 1990-12-31 1994-03-10 藤沢薬品工業株式会社 imidazotriazine derivatives
IL110296A (en) * 1993-07-16 1999-12-31 Smithkline Beecham Corp Imidazole compounds process for their preparation and pharmaceutical compositions containing them
JP2000507558A (en) * 1996-03-25 2000-06-20 スミスクライン・ビーチャム・コーポレイション Novel treatment for CNS injury
US6239279B1 (en) 1998-12-16 2001-05-29 Smithkline Beecham Corporation Synthesis for 4-aryl-5-pyrimidine imidazole substituted derivatives
GB0108770D0 (en) * 2001-04-06 2001-05-30 Eisai London Res Lab Ltd Inhibitors
US7129073B2 (en) * 2001-06-18 2006-10-31 The Rockefeller University Regulation of neuronal function through metabotropic glutamate receptor signaling pathways
WO2005061498A1 (en) * 2003-12-11 2005-07-07 Aventis Pharmaceuticals Inc. Substituted 1h-pyrrolo[3,2-b, 3,2-c, and 2,3-c]pyridine-2-carboxamides and related analogs as inhibitors of casein kinase i epsilon
JO2629B1 (en) * 2004-08-19 2012-06-24 افينتيس فارما سوتيكالز انك Substituted Thenopyrrole carboxylic acid amids, Pyrrolothiazole carboxylic acid amids,and related analogs as inhibitors of casein kinase I epsilon
PL1791537T3 (en) * 2004-08-19 2010-04-30 Aventis Pharma Inc 3-arylthioindole-2-carboxamide derivatives and analogs thereof as inhibitors of casein kinase i
CA2626789A1 (en) * 2005-10-21 2007-04-26 Exelixis, Inc. Pyrimidinones as casein kinase ii (ck2) modulators
EP2308866A1 (en) * 2009-10-09 2011-04-13 Bayer CropScience AG Phenylpyri(mi)dinylpyrazoles and their use as fungicides
PL3181133T3 (en) * 2010-12-20 2019-12-31 Pfizer Inc. Novel fused pyridine compounds as casein kinase inhibitors

Also Published As

Publication number Publication date
CA2777632A1 (en) 2011-05-05
CN102686580A (en) 2012-09-19
US8518944B2 (en) 2013-08-27
TW201125864A (en) 2011-08-01
DK2493876T3 (en) 2014-03-10
KR20120088759A (en) 2012-08-08
CN102686580B (en) 2014-09-10
CA2777632C (en) 2014-02-25
HRP20140252T1 (en) 2014-04-25
PL2493876T3 (en) 2014-06-30
ES2460065T3 (en) 2014-05-13
ZA201202776B (en) 2013-06-26
WO2011051858A1 (en) 2011-05-05
JP5784620B2 (en) 2015-09-24
US20110098272A1 (en) 2011-04-28
MX2012004997A (en) 2012-06-12
AU2010311035B2 (en) 2013-05-16
SI2493876T1 (en) 2014-04-30
EP2493876B1 (en) 2014-02-12
JP2013509392A (en) 2013-03-14
HK1171220A1 (en) 2013-03-22
UY32977A (en) 2011-05-31
PT2493876E (en) 2014-03-20
EP2493876A1 (en) 2012-09-05
IL219190A0 (en) 2012-06-28
AU2010311035A1 (en) 2012-05-03
AR078797A1 (en) 2011-12-07
KR101421852B1 (en) 2014-07-22
RS53246B (en) 2014-08-29

Similar Documents

Publication Publication Date Title
IN2012DN03182A (en)
IN2015DN01119A (en)
GEP20146146B (en) Pyrrolopyrimidine compounds as inhibitors of cdk4/6
WO2007135527A3 (en) Benzimidazolyl compounds
UA99787C2 (en) Lactams as beta secretase inhibitors
CR20200286A (en) Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives
IN2014MN02598A (en)
MX2014012695A (en) Isoindolone derivatives.
MX338551B (en) Novel fused pyridine compounds as casein kinase inhibitors.
MX2014000341A (en) Novel trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease.
NZ608116A (en) Triazine-oxadiazoles
IN2012DN01233A (en)
WO2014045162A8 (en) ALKYL-SUBSTITUTED HEXAHYDROPYRANO[3,4-d] [1,3]THIAZIN-2-AMINE COMPOUNDS
MX2012013274A (en) Novel pyrimidine derivatives.
PH12014501542A1 (en) Substituted pyrrolidine -2- carboxamides
PH12014501514A1 (en) New azetidine derivatives, pharmaceutical compositions and uses thereof
UA104489C2 (en) Compounds for the treatment of dyslipidemia and related diseases
MX342440B (en) Fluorinated aminotriazole derivatives.
WO2012135615A3 (en) Enopeptins, uses thereof, and methods of synthesis thereto
MX2011011083A (en) Heterocyclic compounds as mek inhibitors.
WO2010150211A3 (en) Use of derivatives of indoles for the treatment of cancer
JO2682B1 (en) 7-ALkynyl-1,8-Naphthyridone Derivatives, Preparation Thereof And Therapeutic Use Thereof
MX2013008340A (en) Novel 4-amino-n-hydroxy-benzamides as hdac inhibitors for the treatment of cancer.
MY161749A (en) Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use
WO2010121675A3 (en) Thiazolyl-benzimidazoles